The impact of the COVID-19 pandemic on radiotherapy delivery in Japan: An observational study based on the national database.

Keisuke TamariMaiko KishigamiYasushi NagataTakashi MizowakiTakeshi KodairaHiroshi OnishiKazuhiko OgawaYoshiyuki ShioyamaNaoyuki ShigematsuTakashi Uno

Published in: Cancer medicine (2023)

Overall, radiotherapy delivery in Japan was relatively stable after the pandemic, with an increase in HFRT. Also, EBRT fractions decreased, and breast HFRT were more likely to be used in prefectures with more COVID-19 cases.

Keyphrases

coronavirus disease
sars cov
early stage
locally advanced
radiation induced
radiation therapy
quality improvement
respiratory syndrome coronavirus
squamous cell carcinoma
rectal cancer
emergency department
adverse drug